NSE filing, NSE: DBOL. Summary written from the filing by ALFA Finder's alert engine.
Dhampur Bio Organics Ltd: key numbers
- Share price
- ₹126.14
- Market cap
- ₹837.4 Cr
- Revenue (annual)
- ₹2,109 Cr
- Net profit (annual)
- ₹25.18 Cr
- P/E (TTM)
- 10.0×Sector 26.2×
- Promoter holding
- 51.00%+0.22% QoQ
- FII holding
- 0.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dhampur Bio Organics Ltd
All →Dhampur Bio Organics Management Change
Dhampur Bio Organics Limited announced the cessation of Mr. Surendra Rai Kapur as Cost Auditor due to his demise, effective October 19, 2026.
Dhampur Bio Organics Partnership
Dhampur Bio Organics entered a technology licensing agreement with Planetary SA to produce Mycoprotein, with future plans for a joint venture and offtake agreement.
- Execution
- 10 years
Dhampur Bio Organics Capacity Expansion
Dhampur Bio Organics Ltd. executed a Technology Licensing Agreement with Planetary SA to produce Mycoprotein in India, introducing a new business segment and revenue stream.
Dhampur Bio Organics Other Announcement
The company submitted the certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Dhampur Bio Organics Management Change
Dhampur Bio Organics has promoted Mr. Pankaj Agarwal and Mr. Vinamra Agarwal to Vice President roles. These leadership changes are effective from October 01, 2026.
Dhampur Bio Organics Promoter Buying: ₹1.04 Cr
Promoter group entity Sonitron Limited acquired 85,000 shares of Dhampur Bio Organics Ltd via open market purchases for an aggregate value of ₹1.04 Crore.
- Value
- ₹1.04 Cr
- Promoter stake change
- +0.13%
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr